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Abstract
Background Newborn screening (NBS) by quantifying T cell
receptor excision circles (TRECs) in neonatal dried blood
spots (DBS) enables early diagnosis of severe combined im-
munodeficiency disease (SCID). In recent years, different
screening algorithms for TREC based SCID screening were
reported.
Purpose To systematically review the diagnostic performance
of published algorithms for TREC based NBS for SCID.
Methods PubMed, EMBASE and the Cochrane Library were
systematically searched for case series and prospective cohort
studies describing TREC based NBS for SCID. We extracted
TREC content and cut-off values, number of retests, repeat
DBS and referrals, and type and number of typical SCID
and other T cell lymphopenia (TCL) cases. We calculated
positive predictive value (PPV), test sensitivity and SCID
incidence.
Results Thirteen studies were included, re-confirming 89
known SCID cases in case series and reporting 53 new
SCID cases in 3.15 million newborns. In case series, the sen-
sitivity for typical SCID was 100 %. In the prospective cohort
studies, SCID incidence was ~1.7:100,000, re-test rate was
0.20–3.26 %, repeat DBS rate 0.0–0.41 % and referral rate
0.01–1.35 %. PPV within the five largest cohorts was 0.8–
11.2 % for SCID and 18.3–81.0 % for TCL. Individual
TREC contents in all SCID patients was <25 TRECs/μl (ex-
cept in those evaluated with the New York State assay).
Conclusions The sensitivity of TREC based NBS for typical
SCID was 100 %. The TREC cut-off score determines the
percentage of non-SCID TCL cases detected in newborn
screening for TCL. Adapting the screening algorithm for
pre-term/ill infants reduces the amount of false positive test
results.
Keywords Severe Combined Immunodeficiency .
T-cell lymphopenia . newborn screening . T-cell receptor
excisions circles . screening algorithm . systematic review
Introduction
Severe combined immunodeficiency disease (SCID) is a
group of inherited immunodeficiencies characterized by
T cell lymphopenia (TCL). SCID is recognized as a
pediatric emergency because it leads to severe and re-
current infections and is fatal within the first two years
of life when left untreated [1–3]. Data collected by the
Primary Immune Deficiency Treatment Consortium
demonstrate survival rates of 94 % for those treated
with hematopoietic stem cell transplantation in the first
3.5 months of life, 90 % in older infants without infec-
tions, and 82 % in those with resolved infections. In
contrast, survival of infants older than 3.5 months with
active infection during transplant was only 50 %, indi-
cating that early diagnosis of SCID improves outcome
[4].
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SCID can be detected early by quantifying T-cell receptor
excision circles (TRECs) in Guthrie card dried blood spots
(DBS) using a real time quantitative polymerase chain reac-
tion (RT-qPCR) [5]. Since TRECs are a DNA byproduct of T
cell receptor recombination, low TRECs reflect TCL [6].
Hence, neonatal TREC levels can be used to detect impaired
T cell development and thus to screen for SCID. After a pos-
itive screen, diagnostic follow-up is required to determine
whether the patient suffers from typical SCID or another form
of TCL and to establish a specific genetic diagnosis. The se-
verity of SCID related symptoms, the improved outcome after
early diagnosis, the availability of a screening test in combi-
nation with evidence that newborn screening (NBS) for SCID
is cost-effective [7, 8] demonstrate that SCID fulfills the
Wilson-Jungner screening criteria [9] and identify SCID as a
suitable candidate for NBS.
In 2005, Chan and Puck proposed TREC measurement
for NBS for SCID [5]. A NBS program for SCID using
the TREC assay was successfully initiated in the state of
Wisconsin [10]. This pilot study contributed to the unan-
imous recommendation of the US Secretary’s Advisory
Committee on Heritable Disorders in Newborns and
Children to add SCID to the Recommended Uniform
Newborn Screening Panel in 2010. Since then, NBS for
SCID has been implemented in an increasing number of
states in the USA [7, 11]. Implementation of NBS for
SCID outside the USA is upcoming: pilot studies have
been conducted [12–18] and calls for implementation
have been published [19–21] in Europe, Asia and South
America.
Screening strategies adopted in different states and
countries show heterogeneity. This complicates
decision-making on the design of a uniform algorithm
to use in countries that prepare to implement NBS for
SCID. In general, screening algorithms start with the
quantification of TREC content using RT-qPCR. Several
screening programs measure a housekeeping gene (β-
actin or RNaseP) in parallel in this initial test. An abnor-
mal value results in re-testing of the initial DBS, while
failure of control gene DNA amplification leads to a
request for repeat DBS collection. All algorithms end
with the possibility of referral for diagnostic evaluation
[22]. However, TREC cut-off values, handling of equiv-
ocal or inconclusive results, and handling of subgroups
(e.g., infants born prematurely) vary among different
screening sites.
As more states and countries adopt TREC based NBS, an
increasing number of screening results is published. Questions
that arise from examining results of individual screening sites
include how the TREC content of patients detected at different
screening sites relates to the established diagnosis and local
cut-off values, and how the USA data compare to data gener-
ated outside the USA.
To investigate the difference in diagnostic perfor-
mance of the screening strategies used at various screen-
ing sites, we conducted a systematic review on TREC
based NBS for SCID. We evaluated the diagnostic per-
formance of the individual algorithms based on the num-
ber of retests and repeat samples required, the number of
referrals and the positive predictive value (PPV) for
SCID. The number of retests and repeat samples are sig-
nificant measures of performance, since they reflect the
burden of additional testing exerted on healthy individ-
uals and the health care system. In addition, we com-
pared newborn TREC content of all SCID patients re-
ported in literature as a measure of diagnostic perfor-
mance of different TREC cut-off values. We included
articles discussing USA and non-USA data. By creating
an overview of all available data, we aimed to strengthen
the evidence for implementing NBS for SCID and to
facilitate decision-making on available screening assays
and possible algorithms.
Methods
We conducted a systematic review on the diagnostic perfor-
mance of TREC based NBS for SCID and reported our find-
ings following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [23].
SCID Definitions
We divided reported cases into ‘typical SCID’ (defined
as CD3 T cells<300/μl or maternal engraftment) and
‘other forms of TCL’ (defined as CD3 T cells≥300/μl)
to match the diagnostic criteria for SCID that were re-
cently established by the Primary Immune Deficiency
Treatment Consortium using the data available [24]. In
line with these criteria, we did not classify leaky SCID
and Omenn syndrome as typical SCID. It was not possi-
ble to use the criteria to their full extent because none of
the included publications reported on all parameters re-
quired. When no CD3 values were reported, we catego-
rized the patients as reported by the authors.
Literature Search
We searched PubMed, EMBASE (excl. MEDLINE) and the
Cochrane library on June 20, 2014 for synonyms of Bnewborn
screening^ and Bprimary immunodeficiencies^. Our search
strategy is shown in the Online Resource 1. We checked refer-
ence lists of all included studies for additional sources, includ-
ing government reports. We contacted authors to obtain miss-
ing data and excluded studies with insufficient data to answer
our research queries. During the analysis of the included
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studies, the largest original study on this topic was published;
this study was included in this systematic review as well.
Eligibility Criteria
We identified all studies evaluating TREC based NBS, detect-
ing typical SCID and/or other causes of TCL. Both case series
evaluating TRECs in stored DBS of more than two known
TCL patients and cohort studies in which NBS TRECs were
determined during the neonatal period, were eligible. We
adopted no language restrictions.
Study Selection
Our study selection process is shown in Fig. 1. We screened
the titles and abstracts of all identified records and excluded
articles in a standardized manner. The previously determined
exclusion criteria were applied hierarchically (Fig. 1). Eligible
articles, including those with an eligible title lacking an ab-
stract, were assessed based on full text. If multiple records
described the same screening population, we included the
most recent publication. We included all case series stating
which diagnoses would (not) have been detected by screening.
Cohort studies without details on the TREC cut-off value
and the number of re-tests, repeat DBSs and referrals
were excluded.
Data Extraction
The following items were extracted from all included studies:
geographical location of the study, any parameters added to
the screening panel in addition to TRECs, control gene, TREC
cut-off value, number of newborns included in the study, num-
ber of re-tests on initial DBS specimens (defined as testing a
second punch from the initial Guthrie card), number of
repeat DBSs requested, number of referrals, number of
typical SCID patients, number of other TCL patients,
genetic diagnosis of confirmed typical SCID patients
and diagnoses of other TCL patients. We assumed that
presumptive positive newborns in pilot cohort studies
would have been referred. Since not all studies reported
PPVs and incidences, we calculated the PPV and inci-
dence for SCID and TCL (typical SCID + other TCL)
for all cohort studies based on the reported number of
newborns, referrals and patients.
In addition, we extracted mean normal TREC content
and TREC content of all newborns with a diagnosis that
had been reported to feature TCL in any of the included
studies when reported. Only TREC values derived from
DBS taken at birth were included. To allow for compar-
ison between studies we approximated that (TRECs/reac-
tion)/3 equals TRECs/μl, since a 3.2 mm DBS punch is
estimated to contain 3 μl of blood [13, 25, 26]. Notably,
UK data were obtained using 1.5 mm punches but did
not require conversion because data were reported in
TRECs/μl. We deduced TREC content from graphs when
exact content was not reported. If TREC content of pa-
tients was reported for initial and re-testing separately,
we used mean TREC content.
Assessment of Completeness of Reporting
We assessed the quality and completeness of reporting in the
included studies. Since no standard for reporting screening
studies without a reference standard exists, we developed as-
sessment criteria based on the Standards for Reporting of
Diagnostic Accuracy (STARD) guidelines [27]. Items
reviewed are specified in Online Resource 2. In short, we
assessed accuracy of reporting on the TREC cut-off value,
number of retests, repeat DBSs and referrals, normal TREC
content, cases identified, CD3 counts in cases identified, han-
dling of loss to follow-up and the possibility of missed cases.
Synthesis of Results
We created dot plots of TREC content and corresponding
diagnoses. Additionally, we aimed to improve comparability
between the different TREC assays and cut-off values by plot-
ting the TREC content divided by the cut-off value against the
diagnoses. Because of the heterogeneity of screening strate-
gies, we did not perform diagnostic meta-analysis.
Results
Study Selection
Our search resulted in 340 unique records. After screening
these, we included five case series [28–32], five cohort studies
[12, 25, 26, 33, 34] and two studies describing both a case
series and a cohort [13, 16] (Fig. 1). By checking the
reference lists of included articles we identified two eligi-
ble government reports [11, 35]. However, these were
excluded after full text screening because of incomplete-
ness of data on the number of retests, repeat DBS and
referrals and because complete data were presented in
more recent publications (e.g. [33] for New York State).
We included one extra study describing 11 newborn co-
horts in the USA that was published after the search date
of this review, but was considered important [36]. Four of
these cohorts were partially published earlier [25, 26, 33,
34]. Since more data for data extraction were available in
the earlier published studies, but more newborns were
reported in the most recent study, we extracted data from
earlier studies and the most recent study.
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Completeness of Reporting
We assessed the completeness of reporting in the included
studies based on predefined review criteria (see Online
Resource 2). According to these criteria, reporting was of high
completeness in eleven studies (Online Resource 3). Data col-
lection from the remaining studies [26, 36] was suboptimal,
because of lacking data on retest, repeat DBS and referral rate,
TREC values of individual patients and discussion of loss to
follow-up.
Results of Individual Studies
High Sensitivity for Typical SCID of TREC Based NBS
in Case Series
TREC assays were validated by measuring TREC con-
tent in stored Guthrie cards of patients known to have
SCID or another diagnosis that was hypothesized to be
detected by TREC based NBS. In total 58 of 159 (36 %)
patients included in these case series had typical SCID.
Sensitivity of TREC based NBS in these cases was
100 % for all types of typical SCID tested (Table 1).
Several other types of TCL such as delayed onset
ADA-SCID could not be detected by TREC NBS.
Interestingly, performing the kappa-deleting recombina-
tion excision circles (KREC) assay, which detects B cell
lymphopenia [13, 37, 38], next to the TREC assay (de-
scribed by Borte et al.) enabled detection of delayed-
onset ADA-SCID in neonatal DBSs [39], as did tandem
mass spectrometry [28]. Variations in control genes and
cut-off values used did not influence the correct detec-
tion of SCID patients. Other diagnoses with an abnormal
TREC screening reported in case series included
DiGeorge/22q11 delet ion syndrome and ataxia-
telangiectasia (A-T) (Table 1).
Relevant studies published 
aer search date (1) 
Sources found by screening 
reference lists of included 
arcles: Government reports 
(2) (Excluded based on 
incompleteness of data 
reported) 
Nr. of records excluded: 253
- No original data (65) 
- < 3 paents (58) 
- Animal/preclinical study (17) 
- Irrelevant study topic (33) 
- DBS taken aer neonatal period (64) 
- Screening method other than TRECs (16) 
Arcles idenﬁed by database screening
PubMed: 197 
EMBASE: 170 
Cochrane: 3 
Nr. of records aer removal of duplicates: 340
Nr. of records screened (tle/abstract): 340 
Nr. of records excluded: 75
- No original data (32) 
- < 3 paents (5) 
- Animal/preclinical study (2) 
- DBS taken aer neonatal period (5) 
- Screening method other than TRECs (1) 
- Duplicate data (14) 
- Incomplete data (15)  
- No full text (1)
Nr. of full-text records assessed for eligibility: 87
Nr of records included: 13 
Case series of known paents: 5 
Cohort studies: 6 
Both: 2 
Fig. 1 Flowchart of article
selection for systematic review of
TREC based NBS for SCID.
Exclusion criteria were applied
hierarchically. Studies were
included as case series if stored
Guthrie cards of known patients
were tested. Studies were
included as cohort studies if
newborns were tested
prospectively and sufficient
details on algorithm outcome
were reported
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Variation in Technical Characteristics of Screening Assay
and Algorithm used in Cohort Studies
Table 2 demonstrates the differences between the various
TREC assays and algorithms used at different screening
sites, as far as reported in included articles. Notably,
TREC cut-off values varied from 7 to 252 TRECs/μl.
Furthermore, Guthrie card punches used in the UK were
1.5 mm rather than the standard 3.2 mm as suggested by
the EnLite neonatal TREC kit (Perkin Elmer) [16]. DNA
elution/extraction methods were similar at all screening
sites, with the exception of New York State, where a
wash/red cell lysis buffer was used. Most USA states
used singleplex assays, while multiplex assays were used
outside the USA. The incorporation of a repeat DBS for
prematurely born neonates or NICU patients instead of
referral in case of an abnormal screen, and the addition
of a borderline category at several screening sites, were
the most important differences between screening
algorithms.
TREC Cut-Off Value and Diagnostic Performance in Pilot
Cohort Studies
Data were collected prospectively for approximately 13,000
newborns in pilot cohorts (Table 3). These studies demonstrat-
ed that lowering the TREC cut-off value from 40 to 20
TRECs/μl decreased the retest rate from 3.76 to 0.20 % and
from 2.63 to 1.17 % in the UK and France, respectively, and
referral rates decreased from 1.00 to 0.04 % (UK) and 0.18 to
0.04 % (France). In both countries the lower cut-off value
(UK: 20 TRECs/μl, France: 100 TRECs/reaction) was recom-
mended for future national screening programs. The first pilot
with combined TREC and KREC screening was conducted in
Sweden. Two of the presumptive positive newborns in this
study (33 %) would be referred based on normal TRECs and
abnormal KRECs, resulting in a total referral rate of 0.23 %.
The repeat DBS rate ranged from 0.00 to 0.04 %. Because
Guthrie cards were anonymized in the pilot studies, newborns
with a positive screen were not actually referred and the out-
come of confirmatory diagnostic testing was thus unknown.
Diagnostic Performance of TREC Based NBS
in Population-Based Cohorts Differs Across Studies
Twelve population-based cohorts on TREC based NBS for
SCID were included, detecting a total of 53 typical SCID
cases and 494 cases of other TCL in approximately 3.15 mil-
lion screened newborns (Table 3). The incidence of typical
SCID approximated 1.7:100,000. A high SCID incidence
was reported in Connecticut, Delaware and the Navajo
Nation. In the former two states, however, the incidence was
not significantly different from other screening sites, because
of the relatively low number of newborns screened [36]. The
higher incidence in Navajo Nation is consistent with the
known founder mutation in DCLRE1C [42].
Diagnostic performance differed across studies: retest
rate ranged from 0.00 (Taiwan) to 0.36 % (New York
State), repeat DBS rate from 0.08 (California) to 0.41 %
(Taiwan), and referral rate from 0.01 % (California,
Colorado, Mississippi) to 1.35 % (Texas). Notably, the al-
gorithm used in Texas and Taiwan did not include retesting
of the initial DBS. As compared to the pilot studies, pop-
ulation based studies had higher repeat DBS rates, whereas
the number of referrals was lower.
Within the five largest cohorts, the PPV of the algorithms
for typical SCID ranged from 0.8 % (95 % CI −0.3–1.9 %;
Texas) to 11.2 % (6.9–15.5 %; California), and from 18.3 %
(15.0–21.6 %; New York State) to 81.0 % (71.3–90.6 %;
Massachusetts) for TCL (typical SCID+other TCL).
Differences in outcome were accompanied by variation in
the screening algorithms: TREC cut-off values adopted
ranged from 25 TRECs/μl (California) to 252 TRECs/μl
(Massachusetts). Massachusetts was the only one using a mul-
tiplex assay. In addition, handling of subgroups varied.
Wisconsin and New York State added a repeat DBS prior to
referral in neonates born<37 of gestational age with an abnor-
mal TREC screening. In contrast, California adopted a repeat
DBS for neonatal intensive care unit (NICU) patients with an
abnormal screen.
Diagnoses Detected in Population-Based Cohort Studies
The different types of typical SCID detected in the population-
based cohort studies are displayed in Table 4. The most prev-
alent type was IL2RG-SCID (n=10; 19 % of typical SCID
cases), followed by IL7R-SCID (n=6; 11 %), SCID of un-
known etiology (n=6; 11 %), ADA-SCID (n=5; 9 %),
RAG1-SCID (n=5; 9 %), JAK3-SCID (n=3; 6 %). Other
forms of typical SCID were identified once. Unspecified
TCL (n=117), DiGeorge syndrome (n=83) and cardiac anom-
alies (n=30) were most common. Overall, the diagnoses de-
tected in the cohort studies corresponded to those detected in
case series of known patients (Table 1).
In line with the case series, a case of delayed onset ADA-
SCID was missed by statewide TREC based NBS in
California. None of the other cohort studies reported cases that
were missed by screening. Notably, in Taiwan only part of the
newborn population underwent NBS for SCID. Two addition-
al SCID cases were identified after becoming symptomatic in
the unscreened population. Both infants died. Retrospective
analysis of TREC content in the Guthrie cards of these patients
revealed undetectable TREC content, indicating that both
would likely have been identified if screening would have
been implemented nationwide [26].
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Synthesis of Results
Both pilot and population based cohort studies demonstrated
the impact of the TREC cut-off value on the diagnostic per-
formance of SCID screening algorithms. To establish whether
absolute TREC content of identified patients also differed
across studies, we extracted mean normal TREC content and
the TREC content of individual cases reported in all case
series and cohort studies included.
Normal TREC Content
We aimed to extract normal means and ranges of TREC con-
tent of different studies for optimal evaluation of TREC cut-
off values. Mean normal TREC content, however, were only
reported by three out of seven cohort studies (Online Resource
3). In the UK, mean normal TREC content was 119 TRECs/μl
and median TREC content 101 TRECs/μl (range 0–1160). In
Taiwan, mean TREC content was 283 TRECs/μl and median
202 TRECs/μl. In Wisconsin, mean normal TREC content
was 225 TRECs/μl and median TREC content was 186
TRECs/μl (range <20–5184) [10], whereas mean normal
TREC content was 1900 TRECs/μl [40] in Massachusetts,
and 1832 TRECs/μl (95 % CI 1823–1841) in the New York
State. The large variation in TREC cut-off values was thus
accompanied by a wide spread in normal TREC content.
Individual Patient TREC Content
We extracted the TREC content of all individual SCID/other
TCL patients, as far as these were available in the included
reports. Figure 2 shows the NBS TREC content plotted
against the corresponding diagnoses. TREC content of typical
SCID patients was lower than of patients with other causes of
TCL. In fact, 37 of 80 SCID patients (46 %) displayed in
Fig. 2 had undetectable TREC content, as compared to 18 of
172 non-SCID patients (11 %). Interestingly, higher TREC
content was found in the patients reported by Vogel et al.
[33]. This corresponds to the higher cut-off value used
(Table 2) and the higher normal TREC content found in
New York State. No difference existed between TREC values
per diagnosis reported in case series and cohort studies.
To compensate for the variation in cut-off values, we also
plotted TREC content divided by cut-off value against the
diagnoses (Fig. 3). By applying this calculation, all TREC
values in SCID patients proved to be below the cut-off values,
including the New York State cases. Cases in California were
closest to the Californian stated cut-off value (TRECs/cut-off
up to 0.8 in a patient with Omenn’s SCID).
Finally, we visualized the relation between of the cut-off
score value and the percentage of typical SCID and other TCL
cases identified by TREC screening in Fig. 4. Using a cut-offTa
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score of 25 TRECs/μl, approximately half of the other TCL
cases reported in the included articles were detected.
Discussion
In recent years, effective incorporation of TREC based NBS
for SCID was reported in several studies. Techniques for mea-
suring TRECs and specific screening and referral algorithms
vary between states and countries that have reported success-
ful implementation of SCID NBS. Case series of known pa-
tients confirmed the very high sensitivity of TREC based NBS
for SCID, while prospective cohort studies confirmed the fea-
sibility of screening to identify new SCID cases and signifi-
cantly improve outcome of these patients. The reported inci-
dence of SCID, although approximately twice the incidence
reported before screening [43], was similar across screening
sites, with the exception of Navajo Nation and states with a
small cohort size; therefore, the major differences in PPV
between the larger cohorts (SCID: 0.8–11.2 %, TCL: 18.3–
81.0 %) must be explained by differences in screening
algorithms.
To our knowledge, the present review is the most compre-
hensive review of TREC NBS so far, and it . is the first anal-
ysis of individual TREC content of patients identified by NBS
at different screening sites. An overview of individual TREC
content for SCID and other TCL patients provides new insight
in the influence of the TREC cut-off value on screening effi-
cacy. This systematic review provides an overview of test
characteristics, screening algorithm details, and test per-
formances, and thus facilitates comparing the different
screening programs which can be of help for states and
countries that are in the process of preparing for imple-
mentation of TREC based SCID screening. In the USA,
NBS for SCID for >66 % of the annual newborn popula-
tion was implemented in less than four years [7], demon-
strating the speed with which SCID NBS can be imple-
mented. The impact of SCID NBS will increase in the
Fig. 2 Neonatal TREC content of individual patients with typical SCID
(a) and other TCL (b) diagnoses at different screening sites (colors).
TREC content reported in TRECs/reaction was converted to TRECs/μl.
Partial DiGeorge syndrome and 22q11 deletion syndrome are displayed
together as DiGeorge (b). Thirty three of 74 typical SCID patients
displayed had 0 TRECs, compared to 22 out of 182 other TCL patients.
Anonimyzed SCID patients hadADA-SCID (n=4),γ chain-SCID (n=2),
Omenn-SCID (n=2), RAG-SCID (n=2), PNP-SCID (n=1), undefined
SCID (n=7)
Fig. 3 Neonatal TREC content
of individual patients with typical
SCID (a) and other TCL (b)
diagnoses divided by screening
site-specific TREC cut-off value.
Colors correspond to different
data sources
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coming years, since multiple countries, including Canada
[17], Brazil [14], the UK [16], France [12], Sweden [13],
Germany [13] and also countries with reported high con-
sanguinity rate and SCID incidence [44–46] are in various
stages of implementing population-based SCID NBS.
A comprehensive overview of USA data exists was pre-
sented recently by Kwan et al. (2014). In the current review,
we additionally provide the reported data from screening sites
outside the US, demonstrating the value of recent develop-
ments such as the incorporation of screening for B cell lym-
phopenia by measurement of KREC content [13], as was pro-
posed for incorporation in the USA as well [47]. Furthermore,
this review reports the individual TREC values of typical
SCID and other TCL patients detected by TREC-based
NBS, which is of importance for decision making on identifi-
cation of other causes of TCL that can be identified by TREC
based NBS. Finally, we here report algorithm intermediates
(re-tests and repeat DBS numbers) next to algorithm outcome
(referral), as these numbers are of importance to calculate
screening costs and burden put on individuals.
A decision tool was recently developed to calculate costs
and benefits of SCID screening programs based on local birth
rate, disease incidence and test costs. Assuming 100,000
births per year, an incidence of 1:33,000 and a cost price of
4.25 USD per test, SCID NBS was estimated to reduce SCID
related healthcare costs from 6.0 to ~1.4 million USD annu-
ally in the USA [7]. The demonstrated cost-effectiveness [7, 8,
43], in combination with the clinical benefits, will likely stim-
ulate other countries to also consider SCID NBS.
Recommendations for the Development of SCID
Screening Algorithms
Even though TREC assays were not uniform, individual
TREC content of all SCID cases in both case series and cohort
studies was<25 TRECs/μl, except for two cases identified in
New York State. Of the 74 typical SCID cases for whom
TREC content was available, only the two New York cases
would be missed using a cut-off of 20 TRECs/μl (total
2.7 %). 4.1 % would be missed with a cut-off of<10 TRECs/
μl. Lowering cut-off values will reduce the number of referrals
and thereby the pressure exerted on the health care system,
while not decreasing the sensitivity of NBS for SCID.
Interestingly, the low TREC cut-off value (7 TRECs/μL) used
in Michigan resulted in a relatively low PPV for typical SCID
(1.8 %). The PPV for other TCL, however, was 68.4 %. This
demonstrates that even with a low TREC cut-off value other
non-SCID cases of significant TCL can be identified by NBS
and also shows that not solely the TREC cut-off value, but also
other factors in the PCR assay and algorithm determine PPV.
Results of presently ongoing trials in Sweden and Germany
using a cut-off value of <8 TRECs/μL and <4 KRECs/μL
(reported in [48] and personal communication, Dr. S. Borte)
will provide further insight on using low TREC cut-off values.
NewYork State results deviated from other data, whichmay be
explained by differences in the TREC assay used, e.g., proce-
dure for DNA elution or qPCR conditions (Table 2). Lowering
the TREC cut-off score will still result in identification of typ-
ical SCID cases and will reduce the number of other TCL cases
identified. The cut-off level can thus be adapted to depending
on the patient population that needs to be identified.
Independent of the cut-off level that is used, a diagnostic infra-
structure for further evaluation and clear guidelines for follow-
up need to be established before implementation of TREC
based SCID screening. This is especially true for cases of
non-SCID TCL, because treatment and follow up of these
cases is not always well defined
Adding KRECs next to TRECs to the screening panel
allowed for the detection and thus early treatment of delayed
onset ADA-SCID and primary immunodeficiencies featuring
B cell lymphopenia (e.g., XLA, NBS [13] and possibly AT
[49]). Future studies should reveal whether the benefits of
early diagnosis of primary immunodeficiencies beyond
SCID, as exemplified by the lower risk of chronic lung disease
in XLA in cases diagnosed at young age [50], outweigh the
increase in referral rate.
The highest PPV for typical SCID – but not TCL – was
obtained by the Californian screening program that incorporat-
ed a repeat DBS for neonatal intensive care unit (NICU) pa-
tients with an abnormal screening report. Low TREC content in
NICU patients has been confirmed in other studies [40, 41].
Several screening sites adopted a different cut-off for pre-term
infants or added an extra TREC test at 37 weeks gestational age
prior to referral, which lead to higher PPVs for TCL in
Wisconsin and Delaware than in California. Studies have indi-
cated a higher false positive rate in premature infants and lower
mean TREC values [5, 10, 16, 25, 33]. Depending on whether
new screening sites aim to detect typical SCID or also other
causes of TCL, an extra TREC screen for NICU or premature
infants should be considered as part of the algorithm.
Fig. 4 The percentage of typical SCID and other TCL cases of which the
individual TREC score was below a TREC cut-off score from 0 to 25
TRECs/μl. Patients included in this figure are all patients for which an
individual TREC score was reported in the included articles. Two typical
SCID cases reported by Vogel et al. [33] had a TREC value above 25, as is
consistent with the New York cut-off score of 200 TRECs/μl
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Finally, to allow optimal comparison and to enable coun-
tries and states that newly implement TREC based NBS to
design an evidence-based algorithm optimized for local use,
we recommend the complete reporting of the results (including
exact TREC values per identified case) of all screening sites.
Limitations of Review and Published Studies
The inclusion of all raw screening data from all individual
newborns reported in the included articles, and investigating
the possibility of a universal cut-off value, would be ideal.
These data, however, were not available; therefore, we used
reported TREC content of cases and mean normal TREC con-
tent as the best available alternative. The level of detail pro-
vided on the diagnostic follow-up was not sufficient to allow
us to fully apply the current definitions of SCID. We used
CD3 levels and the vision of the authors of the articles instead.
As a consequence, we could not separate leaky SCID from
typical SCID cases in the USA cohorts.
Since population based NBS for SCID is mainly reported
from the USA, the results presented in this review could re-
flect a selective sample. By including a cohort study from
Taiwan, and several case series from other continents includ-
ing Europe, Asia and South America, we increased the repre-
sentativeness of the results. In fact, of 90 TREC content values
of SCID patients, only 23 were from infants born in the USA.
Results published so far however over-represent the Western
countries. Future results on TREC based NBS from other
regions, for instance those with higher consanguinity rates
[45–47], may yield different data on incidence rates and on
performance of the screening algorithms.
Reporting was not complete in most studies (Online
Resource 3). For example, the study by Chien et al. lacked
several of the items necessary for full description of screening
performance, which indicates that the diagnostic performance
found in this study should be considered with care.
Importantly, no TREC values for detected cases were reported
by Kwan et al. (2014). To allow comparison between future
reports using different screening strategies and cut-off values
we recommend that publications on screening cohorts will
include at least a clear rationale for the cut-off value adopted,
a flowchart with exact numbers of retests, repeat DBS and
referrals, the mean normal TREC content in the population,
details on the diagnosis of confirmed TCL patients, exact in-
dividual NBS TREC content for confirmed TCL patients, a
description of patients who were lost to diagnostic follow-up,
and a discussion of possibly missed cases.
Conclusions
This systematic review of available literature provides an
overview of screening performances of the different
algorithms reported on TREC based SCID NBS. The com-
piled data demonstrate that variation in PCR assay and algo-
rithm features are all determinants of the PPVof SCID NBS,
the most important factor being the TREC cut-off value. The
data in this review suggest that a using a TREC cut-off value
of maximal 25 TRECs/μl and incorporating the collection of a
repeat DBS from NICU patients with an abnormal screening
results in the screening algorithm would be most effective in
screening newborns for primary immunodeficiencies with
TCL. This cut-off value would result in the detection of all
typical SCID cases and the majority of other TCL cases; low-
ering the cut-off score would still lead to the identification of
SCID cases, but reduce the amount of other TCL cases found.
Incorporating an extra TREC test for premature infants prior
to referral could increase the PPV for non-SCID TCL. New
screening sites should therefore adjust their screening algo-
rithm depending on the extent to which they want to identify
non-SCID TCL. The addition of KREC based screening
would allow identification of concurrent B cell lymphopenia,
including patients with delayed-onset ADA-SCID, however a
systematic evaluation of the effectiveness of additional KREC
screening is not available yet.
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